These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10890314)

  • 1. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?
    Palmer JL
    J Psychopharmacol; 2000 Jun; 14(2):186-8. PubMed ID: 10890314
    [No Abstract]   [Full Text] [Related]  

  • 2. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?
    Stanford BJ; Stanford SC
    J Psychopharmacol; 1999; 13(3):313-7. PubMed ID: 10512094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delirium and multiple electrolyte abnormalities associated with high dose paroxetine exposure.
    Chuang YF; Chiu YL; Hwang TJ; Chu TS
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):642-3. PubMed ID: 16958954
    [No Abstract]   [Full Text] [Related]  

  • 4. Delirium induced by abrupt discontinuation of paroxetine.
    Hayakawa Y; Sekine A; Shimizu T
    J Neuropsychiatry Clin Neurosci; 2004; 16(1):119-20. PubMed ID: 14990771
    [No Abstract]   [Full Text] [Related]  

  • 5. Toxic effects of nefazodone.
    Peak DA
    Ann Emerg Med; 1997 Oct; 30(4):551. PubMed ID: 9326874
    [No Abstract]   [Full Text] [Related]  

  • 6. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR.
    DeVane CL
    Psychopharmacol Bull; 2003; 37 Suppl 1():29-41. PubMed ID: 14566199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Paroxetine-induced neuroleptic malignant syndrome].
    Heinemann F; Assion HJ; Hermes G; Ehrlich M
    Nervenarzt; 1997 Aug; 68(8):664-6. PubMed ID: 9380213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.
    Tsao YY; Gugger JJ
    Ann Pharmacother; 2009 Jul; 43(7):1366-9. PubMed ID: 19531695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lawyers may seek judicial review of panel reviewing paroxetine.
    Dobson R
    BMJ; 2003 Mar; 326(7390):618. PubMed ID: 12649225
    [No Abstract]   [Full Text] [Related]  

  • 11. [The seroxat issue].
    Asbøll E
    Tidsskr Nor Laegeforen; 2005 Dec; 125(24):3522-3; author reply 3523. PubMed ID: 16357918
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium.
    Stanford SC; Stanford BJ; Gillman PK
    J Psychopharmacol; 2010 Oct; 24(10):1433-8. PubMed ID: 19423610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hair loss associated with paroxetine treatment: a case report.
    Zalsman G; Sever J; Munitz H
    Clin Neuropharmacol; 1999; 22(4):246-7. PubMed ID: 10442258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxetine: a review of clinical experience.
    Dunner D; Kumar R
    Pharmacopsychiatry; 1998 May; 31(3):89-101. PubMed ID: 9657236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin syndrome after lithium add-on medication to paroxetine.
    Sobanski T; Bagli M; Laux G; Rao ML
    Pharmacopsychiatry; 1997 May; 30(3):106-7. PubMed ID: 9211572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible hepatotoxicity of paroxetine in a patient with major depression.
    Helmchen C; Boerner RJ; Meyendorf R; Hegerl U
    Pharmacopsychiatry; 1996 Nov; 29(6):223-6. PubMed ID: 8956353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil and paroxetine: possible drug interaction.
    Carrier L
    J Am Geriatr Soc; 1999 Aug; 47(8):1037. PubMed ID: 10443872
    [No Abstract]   [Full Text] [Related]  

  • 19. [Persistent interactions].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2010 Mar; 33(3):73. PubMed ID: 20355668
    [No Abstract]   [Full Text] [Related]  

  • 20. Hallucination induced by paroxetine discontinuation in patients with major depressive disorders.
    Yasui-Furukori N; Kaneko S
    Psychiatry Clin Neurosci; 2011 Jun; 65(4):384-5. PubMed ID: 21489048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.